Many patients prescribed glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes or weight management wonder why their medication doesn't seem to be working as expected
This gentle processing method preserves the protein's original nutritional value and amino acid profile
PlexusDx offers flexible dosing options and the Precision Peptide Genetic Test to personalize your long-term treatment plan, ensuring your medication matches your genetic peptide-pathway profile rather than relying on one-size-fits-all dosing
For example, one review noted that GHK-Cu is able to reset the genome to a more functional gene pattern which leads to a better regulation of various cellular pathways in the context of dermal repair
Back to Journals Drug Design, Development and Therapy Volume 17 Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis Authors Xue H, Xing HJ, Wang B, Fu C, Zhang YS, Qiao X, Guo C, Zhang XL, Hu B, Zhao X, Deng LJ, Zhu XC, Zhang Y , Liu YF Received 19 January 2023 Accepted for publication 4 May 2023 Published 11 May 2023 Volume 2023:17 Pages 14171432 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Dr Qiongyu Guo Huan Xue, 1, * Hao-Jie Xing, 1, * Bin Wang, 1 Chao Fu, 1 Yu-Shan Zhang, 1 Xi Qiao, 1 Chao Guo, 1 Xiao-Li Zhang, 1 Bin Hu, 1 Xin Zhao, 1 Li-Jiao Deng, 1 Xiao-Chan Zhu, 1 Yi Zhang, 1 Yun-Feng Liu 2 1 Department of Pharmacology, Shanxi Medical University, Taiyuan, 030001, Peoples Republic of China
Nutritional deficiencies may also cause low energy, but supplementation may help increase your energy and ability to exercise, further enhancing your motivation to lose weight
